UNI-MB - logo
UMNIK - logo
 
Narodna in univerzitetna knjižnica, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Varno zdravljenje gastroezofagealne refluksne bolezni s cisapridom in omeprazolom = Safe use of cisapride and omeprazole in the treatmnet of gastroesophageal reflux disease
    Ivanuša, Marijan, 1966- ; Kocijančič, Borut
    Cisapride is a gastrointestinal prokinetic agent that promotes and co-ordinates peristaltic movements. Owing to a special mechanism of action it possesses a lower potential of producing side effects ... than older prokinetic agents. Metabolic interactions may occur if cisapride is administered concurrently with medications that are metabolised at the cytochrome P450 subunit 3A4 in the liver. There have been reports of individual cases of cardiac arrhythmia, including ventricular tachycardia, ventricular fibrillation, ventricular arrhythmia of the type torsades de pointes and QT interval prolongation. In-depth analyses have demonstrated that the majority of the patients experiencing the above adverse events had been concurrently taking various other medications or had a cardiac condition or were at an increased risk of cardiac arrhythmia. Cisapride may be administered concurrently with medications reducing gastric acid secretion (famotidine, ranitidine, omeprazole, etc). The use of cisapride is safe when due attention is paid to the known contraindications and the correct dosage regimen. Omeprazole is a proton pump inhibitor. It is an inactive prodrug that is accumulated and activated in the secretory canaliculi of the parietal cells where it is covalently bound to thiol groups of the proton pump. This stops the activity of the proton pump and, consequently, acid production. Omeprazoleis the drug of first choice for the treatment of ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. The clinical experience we have gathered with omeprazole is wider than with any other proton pump inhibitor. While the safety of short-term omeprazole treatment hasbeen confirmed several years ago, indisputable evidence has been brought inthe past years, confirming that long-term administration of omeprazole provides a safe therapy as well.
    Vir: Farmacevtski vestnik : strokovno glasilo slovenske farmacije = pharmaceutical journal of Slovenia. - ISSN 0014-8229 (Letn. 51, št. 1, mar. 2000, str. 95-102)
    Vrsta gradiva - članek, sestavni del
    Leto - 2000
    Jezik - slovenski
    COBISS.SI-ID - 12107993

Vnos na polico